Barclays lowered the firm’s price target on Danaher (DHR) to $230 from $250 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is “not without risk.” Sentiment is at all-time lows and Barclays still believes in the “last-cut thesis (for the most part),” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Private Markets: Nuclear, hypersonics score nearly $800M in fresh capital
- Danaher price target lowered, added to ‘Tactical Outperform’ list at Evercore
- Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
- Danaher put volume heavy and directionally bearish
- Palantir upgraded, Workday downgraded: Wall Street’s top analyst calls